Telix Pharmaceuticals - Making progress despite headwinds
The NDA submission for illumet has been delayed slightly by COVID-19 but is expected to be submitted in Q220 (from March-April guidance). A...
108 Views
Telix Pharmaceuticals - Progress on clinical, regulatory and BD fronts
Telix has had a raft of announcements, marking its steady progress in a range of areas. Notably, the company received feedback from the FDA...
642 Views
Telix Pharmaceuticals - Targeted radiation to image and treat cancer
Telix has assembled a portfolio of promising molecularly targeted radiation (MTR) therapeutic and imaging products for three different cancers....
60 Views
Aussie Healthcare Daily: 12 & 13 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...
415 Views